Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Despite the development of novel drugs, the prospects for many patients with acute myeloid leukemia (AML) remain dismal. This study reveals that the selective inhibitor of RNA polymerase I (Pol I) transcription, CX-5461, effectively treats aggressive AML, including mixed-lineage leukemia-driven AML,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Hein, Nadine, Cameron, Donald P., Hannan, Katherine M., Nguyen, Nhu-Y N., Fong, Chun Yew, Sornkom, Jirawas, Wall, Meaghan, Pavy, Megan, Cullinane, Carleen, Diesch, Jeannine, Devlin, Jennifer R., George, Amee J., Sanij, Elaine, Quin, Jaclyn, Poortinga, Gretchen, Verbrugge, Inge, Baker, Adele, Drygin, Denis, Harrison, Simon J., Rozario, James D., Powell, Jason A., Pitson, Stuart M., Zuber, Johannes, Johnstone, Ricky W., Dawson, Mark A., Guthridge, Mark A., Wei, Andrew, McArthur, Grant A., Pearson, Richard B., Hannan, Ross D.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2017
Sujets:
Myeloid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5445570/
https://ncbi.nlm.nih.gov/pubmed/28283481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-05-718171
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires